Maravai Lifesciences Holdings (MRVI) Receivables (2020 - 2026)

Maravai Lifesciences Holdings' Receivables history runs 7 years deep, the most recent figure standing at $33.4 million for Q1 2026.

• In Q1 2026, Receivables rose 17.27% year-over-year to $33.4 million; the TTM figure through Mar 2026 stood at $33.4 million (up 17.27% YoY), while the FY2025 annual figure was $25.5 million, down 33.81% from the prior year.
• Receivables was $33.4 million for Q1 2026 at Maravai Lifesciences Holdings, up from $25.5 million in the prior quarter.
• In the past five years, Receivables ranged from a high of $138.6 million in Q4 2022 to a low of $22.5 million in Q3 2025.
• Historically, Receivables has averaged $57.4 million across 5 years, with a median of $38.5 million in 2024.
• The sharpest annual moves came in 2022 and 2023: Receivables soared 72.99% in 2022, then slumped 60.61% in 2023.
• A 5-year view of Receivables shows it stood at $138.6 million in 2022, then plunged by 60.61% to $54.6 million in 2023, then slipped by 29.46% to $38.5 million in 2024, then tumbled by 33.81% to $25.5 million in 2025, then soared by 31.05% to $33.4 million in 2026.
• The last three Receivables figures came in at $33.4 million (Q1 2026), $25.5 million (Q4 2025), and $22.5 million (Q3 2025), per Business Quant data.